Loading...

HRTX HERON THERAPEUTICS INC Legal Disputes 8-K Filing

HRN

HRTX

HERON THERAPEUTICS INC

(HRTX)

2024 8-K

Show Summary

Show Summary

Financial Statements

Regulatory Compliance

Earnings Results

Loan Agreement Amendment

Headquarters Relocation

Patent Litigation Win

Earnings Announcement

Board Appointment

Earnings Release

FDA Acknowledgment of ZYNRE...

Annual Meeting Approval

Earnings Release

Earnings Release

FDA Approval for ZYNRELEF

Co-Promotion Agreement

Notice of Generic Version

Resignation of Director

Earnings Release

Earnings Release

Equity Offerings

Appointment of CFO

Management Changes

Financial Results Announcement

Departure of Directors and ...

Appointment of CEO and Chai...

External Links:

Heron Therapeutics won a court ruling confirming the validity of its patents for CINVANTI, preventing Fresenius Kabi from launching a generic version before 2035.

AI Assistant

HERON THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.